Rupatadine - Pediapharm

Drug Profile

Rupatadine - Pediapharm

Alternative Names: Alergoliber; Rupafin; Rupall; Rupatadine fumarate; TK-041; UR 12592

Latest Information Update: 23 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Uriach
  • Developer Pediapharm; Teikoku Seiyaku; Uriach
  • Class Antiallergics; Dibenzocycloheptenes; Nonsedating antihistamines; Piperidines; Small molecules
  • Mechanism of Action Histamine H1 receptor antagonists; Platelet activating factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Perennial allergic rhinitis; Seasonal allergic rhinitis; Urticaria
  • Registered Pruritus
  • Discontinued Atopic dermatitis; Dermatitis

Most Recent Events

  • 22 Nov 2017 Teikoku Seiyaku and Mitsubishi Tanabe Pharma Corporation intend to launch rupatadine fumarate (Rupafin®) in Japan on November 27, 2017
  • 27 Sep 2017 Registered for Pruritus, Seasonal allergic rhinitis, Perennial allergic rhinitis and Urticaria in Japan (PO, Tablet) (PMDA website)
  • 25 Jan 2017 Launched for Perennial allergic rhinitis, Seasonal allergic rhinitis and Urticaria (In adolescents, In children, In adults) in Canada (PO, Tablet, Liquid)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top